Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 18/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.42 |
| ▸ | CASP1 | P29466 | 6/20 | 0.42 |
| ▸ | CASP7 | P55210 | 5/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 9/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090527 | 0.84 | CYP1A2 (0.45) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL4137122 | 0.84 | CYP1A2 (0.42) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL4139913 | 0.81 | KCNH2 (0.49) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL12090780 | 0.80 | KMT2A (0.42) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL4142229 | 0.78 | ALDH1A1 (0.42) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL4141484 | 0.77 | CYP1A2 (0.37) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL2798622 | 0.76 | ALDH1A1 (0.43) | CYP1A2ALDH1A1HSD17B10CASP1MAPK1 | |
| SCHEMBL4153118 | 0.76 | CYP1A2 (0.44) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL4143815 | 0.75 | CYP1A2 (0.39) | CYP1A2ALDH1A1HSD17B10CASP1CASP7 | |
| SCHEMBL2795578 | 0.72 | KDM4E (0.64) | ALDH1A1HSD17B10MAPK1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| EP-2022793-B1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367831-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211908-B2 | Heterocyclic compound or salt thereof and intermediate thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, H1-4 | CYP1A2 1852/4885ALDH1A1 3789/4885HSD17B10 1478/4885 |
| US-20120226035-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | IKZF3, ZC3HAV1L, CXXC5 | CYP1A2 1723/4885ALDH1A1 3409/4885HSD17B10 1172/4885 |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | CYP1A2 1342/4885ALDH1A1 3693/4885HSD17B10 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.